Inari Medical, Inc. (NASDAQ:NARI) Shares Sold by Holocene Advisors LP

Holocene Advisors LP trimmed its stake in Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 68.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 15,781 shares of the company's stock after selling 34,142 shares during the quarter. Holocene Advisors LP's holdings in Inari Medical were worth $651,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the company. Vestal Point Capital LP boosted its stake in Inari Medical by 342.9% during the 3rd quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company's stock valued at $63,922,000 after purchasing an additional 1,200,000 shares in the last quarter. Point72 Asset Management L.P. raised its position in Inari Medical by 113.3% during the second quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company's stock valued at $71,324,000 after buying an additional 786,691 shares during the period. Armistice Capital LLC increased its position in Inari Medical by 353.1% in the 2nd quarter. Armistice Capital LLC now owns 1,009,252 shares of the company's stock worth $48,595,000 after purchasing an additional 786,501 shares during the last quarter. Jennison Associates LLC increased its position in Inari Medical by 63.2% in the 3rd quarter. Jennison Associates LLC now owns 1,576,641 shares of the company's stock worth $65,021,000 after purchasing an additional 610,468 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Inari Medical by 101.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 795,099 shares of the company's stock valued at $32,790,000 after acquiring an additional 400,198 shares during the last quarter. 90.98% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Inari Medical

In other Inari Medical news, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the sale, the chief executive officer now directly owns 445,310 shares in the company, valued at approximately $22,265,500. The trade was a 0.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William Hoffman sold 40,000 shares of the company's stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total transaction of $1,800,800.00. Following the transaction, the director now owns 601,233 shares in the company, valued at $27,067,509.66. The trade was a 6.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 186,000 shares of company stock valued at $8,990,990. Corporate insiders own 10.60% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on the company. Robert W. Baird raised their price objective on Inari Medical from $66.00 to $67.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 29th. Needham & Company LLC restated a "hold" rating on shares of Inari Medical in a research report on Tuesday, October 29th. Leerink Partners started coverage on Inari Medical in a report on Tuesday, September 3rd. They issued a "market perform" rating and a $47.00 price target on the stock. Stifel Nicolaus assumed coverage on Inari Medical in a research report on Tuesday, September 17th. They issued a "hold" rating and a $50.00 price objective for the company. Finally, Canaccord Genuity Group increased their target price on Inari Medical from $71.00 to $74.00 and gave the stock a "buy" rating in a research note on Tuesday, October 29th. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $58.89.

Inari Medical Stock Down 0.9 %

Shares of Inari Medical stock traded down $0.48 during trading on Friday, reaching $51.08. 809,525 shares of the stock were exchanged, compared to its average volume of 667,190. The stock's fifty day moving average is $47.30 and its 200 day moving average is $47.73. The firm has a market cap of $2.99 billion, a price-to-earnings ratio of -37.84 and a beta of 0.97. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $67.13.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.